CN109415414A - 变体黄病毒包膜序列及其用途 - Google Patents

变体黄病毒包膜序列及其用途 Download PDF

Info

Publication number
CN109415414A
CN109415414A CN201780040802.7A CN201780040802A CN109415414A CN 109415414 A CN109415414 A CN 109415414A CN 201780040802 A CN201780040802 A CN 201780040802A CN 109415414 A CN109415414 A CN 109415414A
Authority
CN
China
Prior art keywords
analog
protein
antibody
flavivirus
dengue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780040802.7A
Other languages
English (en)
Chinese (zh)
Inventor
皮特·莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Igsevien Co Ltd
Original Assignee
Igsevien Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igsevien Co Ltd filed Critical Igsevien Co Ltd
Publication of CN109415414A publication Critical patent/CN109415414A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
CN201780040802.7A 2016-05-20 2017-05-22 变体黄病毒包膜序列及其用途 Pending CN109415414A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
GB1608896.5 2016-05-20
PCT/US2017/033882 WO2017201543A1 (en) 2016-05-20 2017-05-22 Variant flavivirus envelope sequences and uses thereof

Publications (1)

Publication Number Publication Date
CN109415414A true CN109415414A (zh) 2019-03-01

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780040802.7A Pending CN109415414A (zh) 2016-05-20 2017-05-22 变体黄病毒包膜序列及其用途

Country Status (18)

Country Link
US (2) US11028133B2 (enExample)
EP (2) EP3458471B1 (enExample)
JP (1) JP7121396B2 (enExample)
KR (1) KR20190008896A (enExample)
CN (1) CN109415414A (enExample)
AU (1) AU2017268479B2 (enExample)
BR (1) BR112018073681A2 (enExample)
CA (1) CA3025076A1 (enExample)
DK (1) DK3458471T3 (enExample)
GB (2) GB2550418A (enExample)
HU (1) HUE049543T2 (enExample)
IL (1) IL263054A (enExample)
MX (1) MX2018014198A (enExample)
PE (1) PE20190130A1 (enExample)
PH (1) PH12018502441A1 (enExample)
RU (1) RU2018142835A (enExample)
SG (1) SG11201810157QA (enExample)
WO (2) WO2017201543A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907456A (zh) * 2019-11-07 2022-08-16 中国科学院微生物研究所 一种寨卡/登革疫苗及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
EP3838290A1 (en) * 2016-06-23 2021-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions comprising an attenuated mutant zika virus
US11793873B2 (en) * 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
AU2021357746A1 (en) * 2020-10-07 2023-06-15 Ctk Biotech, Inc. Improved diagnostic tests
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
EP4602057A1 (en) * 2022-10-11 2025-08-20 University of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015783A2 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
CN104428312A (zh) * 2012-04-02 2015-03-18 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
WO2016012800A1 (en) * 2014-07-23 2016-01-28 Imperial Innovations Limited Anti-dengue vaccines and antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007015783A2 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
CN104428312A (zh) * 2012-04-02 2015-03-18 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
WO2016012800A1 (en) * 2014-07-23 2016-01-28 Imperial Innovations Limited Anti-dengue vaccines and antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
房树玉等: "登革病毒包膜蛋白的原核表达及免疫原性研究", 《微生物与感染》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907456A (zh) * 2019-11-07 2022-08-16 中国科学院微生物研究所 一种寨卡/登革疫苗及其应用
CN114907457A (zh) * 2019-11-07 2022-08-16 中国科学院微生物研究所 一种寨卡/登革疫苗及其应用
CN114907457B (zh) * 2019-11-07 2025-05-30 中国科学院微生物研究所 一种寨卡/登革疫苗及其应用
CN114907456B (zh) * 2019-11-07 2025-05-30 中国科学院微生物研究所 一种寨卡/登革疫苗及其应用

Also Published As

Publication number Publication date
US20200215180A1 (en) 2020-07-09
HUE049543T2 (hu) 2020-09-28
US11028133B2 (en) 2021-06-08
AU2017268479B2 (en) 2021-04-01
IL263054A (en) 2019-01-31
BR112018073681A2 (pt) 2019-02-26
EP3458471B1 (en) 2020-03-25
WO2018215495A1 (en) 2018-11-29
RU2018142835A (ru) 2020-06-22
MX2018014198A (es) 2019-08-21
AU2017268479A1 (en) 2018-12-06
GB201719423D0 (en) 2018-01-03
PH12018502441A1 (en) 2019-05-15
EP3630796A1 (en) 2020-04-08
GB2550418A (en) 2017-11-22
EP3458471A1 (en) 2019-03-27
KR20190008896A (ko) 2019-01-25
SG11201810157QA (en) 2018-12-28
PE20190130A1 (es) 2019-01-17
JP2019520058A (ja) 2019-07-18
CA3025076A1 (en) 2017-11-23
JP7121396B2 (ja) 2022-08-18
DK3458471T3 (da) 2020-07-06
WO2017201543A1 (en) 2017-11-23
GB201608896D0 (en) 2016-07-06
US20190300580A1 (en) 2019-10-03
US11401307B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
CN109415414A (zh) 变体黄病毒包膜序列及其用途
Murin et al. Antibody responses to viral infections: a structural perspective across three different enveloped viruses
US12415836B2 (en) Anti-dengue vaccines and antibodies
US11926648B2 (en) Neutralising antibody against dengue for use in a method of prevention and/or treatment of Zika infection
Poggianella et al. Dengue E protein domain III-based DNA immunisation induces strong antibody responses to all four viral serotypes
KR20010022452A (ko) 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
Staropoli et al. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice
AU4329699A (en) Nucleic acid vaccines for prevention of flavivirus infection
CN106574271B (zh) 嵌合西尼罗/登革病毒和使用方法
US20220017605A1 (en) Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
US7595053B2 (en) Chimeric T helper-B cell peptide vaccine for Japanese encephalitis virus
US10772949B2 (en) Dengue virus glycoprotein E DIII variants and uses thereof
HK1261267A1 (en) Variant flavivirus envelope sequences and uses thereof
Thiono The Effect of Dengue Virus 2 Envelope Proteins as Vaccine Antigens on Neutralizing Antibody Responses
Chao et al. A dengue monovalent vaccine with novel structure provides cross-protection against four serotypes of dengue virus
Calvert et al. The use of human monoclonal antibodies to study the structure and function of the West Nile virus prM protein
Dengue Chimpanzee Fab Fragments and a Derived
BR112017001340B1 (pt) Epítopo de dímero e, composição, composição farmacêutica, kit, método para a síntese do ede e para produzir um anticorpo ou porção de ligação ao antígeno do mesmo, método in vitro para monitorar a progressão ou regressão de uma infecção por vírus da dengue ou prever a evolução no tempo da mesma, para diagnosticar uma infecção por vírus da dengue e para monitorar o sucesso de um protocolo de vacinação contra uma infecção de vírus da dengue e usos dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261267

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1261267

Country of ref document: HK